News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
267,209 Results
Type
Article (14225)
Company Profile (282)
Press Release (252702)
Multimedia
Podcasts (48)
Webinars (7)
Section
Business (79521)
Career Advice (153)
Deals (13228)
Drug Delivery (35)
Drug Development (50453)
Employer Resources (31)
FDA (5722)
Job Trends (5129)
News (144420)
Policy (10035)
Tag
2024 BioCapital Digital (6)
2024 BioForest Digital (1)
2024 BioMidwest Digital (4)
2024 Bio NC Digital (4)
2024 Biotech Bay Standard (11)
2024 Biotech Beach Digital (5)
2024 Biotech Beach Standard (3)
2024 Genetown Digital (7)
2024 Genetown Standard (6)
2024 Lone Star Bio Digital (4)
2024 Pharm Country Digital (4)
2024 Pharm Country Standard (3)
2025 BioForest Digital (3)
2025 Lone Star Bio Digital (3)
2026 BioMidwest Elite (1)
2026 Bio NC Standard (1)
2026 Biotech Bay Elite (1)
2026 Biotech Bay Standard (1)
2026 Biotech Beach Elite (1)
2026 Genetown Elite (2)
2026 Genetown Standard (1)
2026 Pharm Country Elite (1)
2026 Pharm Country Standard (1)
Academia (914)
Accelerated approval (2)
Adcomms (12)
Allergies (51)
Alliances (21657)
ALS (63)
Alzheimer's disease (842)
Antibody-drug conjugate (ADC) (89)
Approvals (5741)
Artificial intelligence (116)
Autoimmune disease (17)
Automation (5)
Bankruptcy (104)
Best Places to Work (4560)
BIOSECURE Act (5)
Biosimilars (42)
Biotechnology (232)
Bladder cancer (47)
Brain cancer (20)
Breast cancer (144)
Cancer (1354)
Cardiovascular disease (115)
Career advice (133)
Career pathing (2)
CAR-T (110)
Cell therapy (312)
Cervical cancer (8)
Clinical research (40978)
Collaboration (512)
Compensation (247)
Complete response letters (13)
COVID-19 (1034)
CRISPR (39)
C-suite (153)
Cystic fibrosis (76)
Data (1420)
Denatured (11)
Depression (29)
Diabetes (129)
Diagnostics (1294)
Digital health (3)
Diversity (2)
Diversity, equity & inclusion (9)
Drug discovery (81)
Drug pricing (28)
Drug shortages (3)
Duchenne muscular dystrophy (88)
Earnings (29727)
Editorial (18)
Employer branding (4)
Employer resources (29)
Events (48276)
Executive appointments (430)
FDA (6378)
Featured Employer (31)
Fibrodysplasia Ossificans Progressiva (1)
Friedreich's ataxia (4)
Frontotemporal dementia (7)
Funding (482)
Gene editing (93)
Generative AI (10)
Gene therapy (239)
GLP-1 (362)
Government (1079)
Grass and pollen (2)
Guidances (18)
Healthcare (6593)
Huntington's disease (21)
IgA nephropathy (22)
Immunology and inflammation (86)
Indications (18)
Infectious disease (1099)
Inflammatory bowel disease (111)
Inflation Reduction Act (8)
Influenza (19)
Intellectual property (61)
Interviews (17)
IPO (7268)
IRA (11)
Job creations (860)
Job search strategy (127)
Kidney cancer (6)
Labor market (4)
Layoffs (204)
Leadership (3)
Legal (1388)
Liver cancer (31)
Lung cancer (193)
Lymphoma (89)
Machine learning (2)
Management (7)
Manufacturing (122)
MASH (50)
Medical device (2593)
Medtech (2594)
Mergers & acquisitions (6272)
Metabolic disorders (375)
Multiple sclerosis (51)
NASH (13)
Neurodegenerative disease (63)
Neuropsychiatric disorders (23)
Neuroscience (1231)
NextGen: Class of 2025 (2018)
Non-profit (853)
Northern California (1617)
Now hiring (21)
Obesity (191)
Opinion (102)
Ovarian cancer (61)
Pain (41)
Pancreatic cancer (52)
Parkinson's disease (118)
Partnered (8)
Patents (121)
Patient recruitment (69)
Peanut (35)
People (25570)
Pharmaceutical (48)
Pharmacy benefit managers (5)
Phase I (14473)
Phase II (19062)
Phase III (12055)
Pipeline (774)
Policy (43)
Postmarket research (852)
Preclinical (6078)
Press Release (30)
Prostate cancer (57)
Psychedelics (35)
Radiopharmaceuticals (212)
Rare diseases (285)
Real estate (1418)
Recruiting (12)
Regulatory (8601)
Reports (15)
Research institute (938)
Resumes & cover letters (17)
Rett syndrome (4)
RNA editing (4)
RSV (10)
Schizophrenia (57)
Series A (95)
Series B (60)
Service/supplier (1)
Sickle cell disease (40)
Southern California (1427)
Special edition (11)
Spinal muscular atrophy (117)
Sponsored (11)
Startups (1972)
State (1)
Stomach cancer (4)
Supply chain (20)
Tariffs (4)
The Weekly (36)
United States (12591)
Vaccines (207)
Venture capitalists (28)
Weight loss (108)
Women's health (15)
Worklife (2)
Date
Today (69)
Last 7 days (258)
Last 30 days (1499)
Last 365 days (19700)
2025 (5368)
2024 (20552)
2023 (22414)
2022 (26822)
2021 (27806)
2020 (23358)
2019 (16227)
2018 (11741)
2017 (13747)
2016 (11840)
2015 (14349)
2014 (10392)
2013 (7484)
2012 (7532)
2011 (7614)
2010 (7429)
Location
Africa (148)
Alabama (41)
Alaska (2)
Arizona (53)
Arkansas (5)
Asia (17250)
Australia (2927)
California (3661)
Canada (1089)
China (332)
Colorado (139)
Connecticut (147)
Delaware (92)
Europe (37114)
Florida (436)
Georgia (114)
Idaho (16)
Illinois (216)
India (10)
Indiana (90)
Iowa (1)
Japan (73)
Kansas (61)
Kentucky (5)
Louisiana (3)
Maine (11)
Maryland (455)
Massachusetts (2895)
Michigan (70)
Minnesota (141)
Mississippi (1)
Missouri (24)
Montana (14)
Nebraska (4)
Nevada (16)
New Hampshire (14)
New Jersey (922)
New Mexico (12)
New York (993)
North Carolina (534)
North Dakota (4)
Northern California (1617)
Ohio (109)
Oklahoma (9)
Oregon (21)
Pennsylvania (693)
Puerto Rico (5)
Rhode Island (15)
South America (208)
South Carolina (4)
Southern California (1427)
Tennessee (25)
Texas (419)
Utah (50)
Virginia (74)
Washington D.C. (30)
Washington State (336)
Wisconsin (14)
267,209 Results for "tempest therapeutics".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Funding
Tempest Scrambles for Ways to Bankroll Late-Stage Liver Cancer Asset
According to Tempest, its options include a partnership or licensing deal, as well as a merger or an acquisition.
April 10, 2025
·
2 min read
·
Tristan Manalac
Press Releases
Tempest Reports Year End 2024 Financial Results and Provides Business Update
March 28, 2025
·
9 min read
Press Releases
Tempest Announces Plan to Explore Strategic Alternatives to Advance Promising Pipeline of Clinical Oncology Assets and Maximize Stockholder Value
April 10, 2025
·
9 min read
Press Releases
Tempest Announces Amezalpat Poster Presentation at the 2025 American Association for Cancer Research (AACR) Annual Meeting
March 25, 2025
·
4 min read
Press Releases
Tempest Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - February 7, 2025
February 9, 2025
·
1 min read
Biotech Bay
Tempest to Participate in Upcoming Investor Conferences - May 21, 2024
Tempest Therapeutics, Inc., a clinical-stage biotechnology company developing first-in-classi targeted and immune-mediated therapeutics to fight cancer, announced that management will participate in the following upcoming investor conferences.
May 21, 2024
·
1 min read
Press Releases
Tempest Granted Fast Track Designation from the U.S. Food and Drug Administration for Amezalpat to Treat Patients with Hepatocellular Carcinoma
February 10, 2025
·
7 min read
Drug Development
Tempest Unveils New Survival Data for Amezalpat (TPST-1120) in Randomized First-Line HCC Study Demonstrating a Six-Month Improvement over Control Arm
Tempest Therapeutics, Inc. announced new positive data from the ongoing global randomized Phase 1b/2 clinical study in which amezalpat2, Tempest’s PPAR⍺ antagonist, delivered a six-month improvement in median overall survival advantage when combined with atezolizumab and bevacizumab in a comparison to atezolizumab and bevacizumab alone in the first-line treatment of patients with unresectable or metastatic hepatocellular carcinoma.
June 20, 2024
·
9 min read
Business
Tempest Reports First Quarter 2024 Financial Results and Provides Business Update
Tempest Therapeutics, Inc., a clinical-stage biotechnology company developing first-in-classi targeted and immune-mediated therapeutics to fight cancer, reported financial results for the quarter ended March 31, 2024, and provided a corporate update.
May 9, 2024
·
8 min read
Press Releases
Tempest to Participate in the Piper Sandler 36th Annual Healthcare Conference
November 25, 2024
·
1 min read
1 of 26,721
Next
